CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

HIV treatment has entered a revolutionary new era, one where a single yearly injection can keep the virus undetectable, and ...

The gene editing market is experiencing significant growth, with a projected annual growth rate (CAGR) of 16-18% in the coming years. This expansion is fueled by breakthroughs in gene-editing ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...

From custom gene editing to a discovery that could help stop pancreatic cancer before it starts, these advances offer a ...

New gene-editing tools – most notably the Nobel Prize-winning CRISPR-Cas9 – allow targeted tweaks to a crop’s genome, ...

Sofi-cel is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy currently under evaluation in a pivotal trial (T-RRex) for patients with relapsed or refractory (R/R) ...

The "Mice Model Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering.The mice model market is experiencing robust growth, with projected expansion from USD 1.61 ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing ...